Multimorbidity in chronic disease: Impact on health care resources and costs

Risk Management and Healthcare Policy

Volumn 9, Issue , 2016, Pages 143-156

  McPhail, Steven M ^a,b  

^a Metro South Health Services District   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Burden; Chronic disease; Comorbidity; Complexity; Cost effectiveness; Economic

Indexed keywords

CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG USE; EMERGENCY TREATMENT; EMERGENCY WARD; FUNDING; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MULTIMORBIDITY; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH PRIORITY; RESOURCE ALLOCATION; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC);

EID: 84982299865     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: 10.2147/RMHP.S97248     Document Type: Review

References (145)

1. Lehnert T, Heider D, Leicht H, et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011;68(4):387-420.
2. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns. 2002;48(2):177-187.
3. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716-724.
4. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness which ones work? Meta-analysis of published reports. BMJ. 2002;325(7370):925.
5. McPhail SM, Schippers M, Marshall AL, Waite M, Kuipers P. Perceived barriers and facilitators to increasing physical activity among people with musculoskeletal disorders: a qualitative investigation to inform intervention development. Clin Interv Aging. 2014;9:2113-2122.
6. Onder G, Palmer K, Navickas R, et al. Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). Eur J Intern Med. 2015;26(3):157-159.
7. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269-2276.
8. Brown RS, Peikes D, Peterson G, Schore J, Razafindrakoto CM. Six features of Medicare coordinated care demonstration programs that cut hospital admissions of high-risk patients. Health Aff. 2012; 31(6):1156-1166.
9. Wittenberg R. The challenge of measuring multi-morbidity and its costs. Isr J Health Policy Res. 2015;4:1.
10. McPhail SM, Schippers M, Marshall AL. Age, physical inactivity, obesity, health conditions, and health-related quality of life among patients receiving conservative management for musculoskeletal disorders. Clin Interv Aging. 2014;9:1069-1080.
11. Lefèvre T, d’Ivernois JF, De Andrade V, Crozet C, Lombrail P, Gagnayre R. What do we mean by multimorbidity? An analysis of the literature on multimorbidity measures, associated factors, and impact on health services organization. Rev Epidemiol Sante Publique. 2014;62(5):305-314.
12. Damery S, Flanagan S, Combes G. The effectiveness of interventions to achieve co-ordinated multidisciplinary care and reduce hospital use for people with chronic diseases: study protocol for a systematic review of reviews. Syst Rev. 2015;4:64.
13. Huntley AL, Johnson R, Purdy S, Valderas JM, Salisbury C. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med. 2012;10(2):134-141.
14. Smith SM, Soubhi H, Fortin M, Hudon C, O’Dowd T. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
15. Yurkovich M, Avina-Zubieta JA, Thomas J, Gorenchtein M, Lacaille D. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol. 2015;68(1):3-14.
16. Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Gen Intern Med. 2007;22(4):464-469.
17. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234-1240.
18. Perkins AJ, Kroenke K, Unützer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol. 2004;57(10):1040-1048.
19. Zulman DM, Chee CP, Wagner TH, et al. Multimorbidity and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System. BMJ Open. 2015;5(4):e007771.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
21. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12): 1288-1294.
22. Clark DO, Korff MV, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783-795.
23. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357-363.
24. Calderón-Larrañaga A, Abad-Díez JM, Gimeno-Feliu LA, et al. Global health care use by patients with type-2 diabetes: does the type of comorbidity matter? Eur J Intern Med. 2015;26(3):203-210.
25. Bernabeu-Wittel M, Alonso-Coello P, Rico-Blázquez M, Rotaeche del Campo R, Sánchez Gómez S, Casariego Vales E. Development of clinical practice guidelines for patients with comorbidity and multiple diseases. Rev Clín Esp. 2014;214(6):328-335.
26. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med. 2012;10(2):142-151.
27. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858.
28. El-Atem NA, Wojcik K, Horsfall L, et al. Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease. Intern Med J. 2016;46(4):420-426.
29. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43.
30. Dixon A, Khachatryan A, Gilmour S. Does general practice reduce health inequalities? Analysis of quality and outcomes framework data. Eur J Public Health. 2012;22(1):9-13.
31. Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87(10):1626-1629.
32. Sloane PD, Oudenhoven MD, Broyles I, McNabney M. Challenges to cost-effective care of older adults with multiple chronic conditions: perspectives of Program of All-Inclusive Care for the Elderly medical directors. J Am Geriatr Soc. 2014;62(3):564-565.
33. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? Health Aff. 2009;28(1):64-74.
34. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8): 933-944.
35. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815-825.
36. Fox MH, Reichard A. Disability, health, and multiple chronic conditions among people eligible for both Medicare and Medicaid, 2005-2010. Prev Chronic Dis. 2013;10:E157.
37. Lawson KD, Mercer SW, Wyke S, et al. Double trouble: the impact of multimorbidity and deprivation on preference-weighted health related quality of life a cross sectional analysis of the Scottish Health Survey. Int J Equity Health. 2013;12:67.
38. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-2260.
39. McPhail S, Schippers M. An evolving perspective on physical activity counselling by medical professionals. BMC Fam Pract. 2012;13(1):31.
40. Dixon A, Khachatryan A, Wallace A, Peckham S, Boyce T, Gillam S. The quality and outcomes framework (QOF): does it reduce health inequalities. Final report. London, UK: NIHR; 2010.
41. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition - multimorbidity. JAMA. 2012;307(23):2493-2494.
42. Salisbury C. Multimorbidity: redesigning health care for people who use it. Lancet. 2012;380(9836):7-9.
43. Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18(1):12-28.
44. Bohensky MA, Ademi Z, deSteiger R, et al. Quantifying the excess cost and resource utilisation for patients with complications associated with elective knee arthroscopy: a retrospective cohort study. Knee. 2014;21(2):491-496.
45. Crystal S, Johnson RW, Harman J, Sambamoorthi U, Kumar R. Outof- pocket health care costs among older Americans. J Gerontol B Psychol Sci Soc Sci. 2000;55(1):S51-S62.
46. Karve S, Candrilli S, Kappelman MD, Tolleson-Rinehart S, Tennis P, Andrews E. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr. 2012;161(4):662-670.e662.
47. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health. 2001;4(4): 329-334.
48. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
49. Hunger M, Thorand B, Schunk M, et al. Multimorbidity and healthrelated quality of life in the older population: results from the German KORA-age study. Health Qual Life Outcomes. 2011;9(1):1-10.
50. Marventano S, Ayala A, Gonzalez N, Rodríguez-Blázquez C, Garcia- Gutierrez S, Forjaz MJ. Multimorbidity and functional status in community- dwelling older adults. Eur J Intern Med. 2014;25(7):610-616.
51. Tyack Z, Frakes KA, Barnett A, Cornwell P, Kuys S, McPhail S. Predictors of health-related quality of life in people with a complex chronic disease including multimorbidity: a longitudinal cohort study. Qual Life Res. 2016. Epub April 5, 2016.
52. Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation overview of the Australian National Mental Health Survey. Br J Psychiatry. 2001;178(2):145-153.
53. Hopman P, Heins MJ, Rijken M, Schellevis FG. Health care utilization of patients with multiple chronic diseases in The Netherlands: Differences and underlying factors. Eur J Intern Med. 2015;26(3): 190-196.
54. Fahlman C, Lynn J, Doberman D, Gabel J, Finch M. Prescription drug spending for Medicare+ Choice beneficiaries in the last year of life. J Palliat Med. 2006;9(4):884-893.
55. Moxey ED, O’Connor JP, Novielli KD, Teutsch S, Nash DB. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 2002;24(4):127-141.
56. Ramage-Morin PL. Medication use among senior Canadians. Health Rep. 2009;20(1):37-44.
57. Rogowski J, Lillard LA, Kington R. The financial burden of prescription drug use among elderly persons. Gerontologist. 1997;37(4):475-482.
58. Landis SE, Gaynes BN, Morrissey JP, Vinson N, Ellis AR, Domino ME. Generalist care managers for the treatment of depressed medicaid patients in North Carolina: a pilot study. BMC Fam Pract. 2007;8:7.
59. Starfield B, Lemke KW, Bernhardt T, Foldes SS, Forrest CB, Weiner JP. Comorbidity: implications for the importance of primary care in “case” management. Ann Fam Med. 2003;1(1):8-14.
60. Chan DK, Chong R, Basilikas J, Mathie M, Hung WT. Survey of major chronic illnesses and hospital admissions via the emergency department in a randomized older population in Randwick, Australia. Emerg Med. 2002;14(4):387-392.
61. Chu LW, Pei CK. Risk factors for early emergency hospital readmission in elderly medical patients. Gerontology. 1999;45(4):220-226.
62. Condelius A, Edberg AK, Jakobsson U, Hallberg IR. Hospital admissions among people 65+ related to multimorbidity, municipal and outpatient care. Arch Gerontol Geriatr. 2008;46(1):41-55.
63. Rapoport J, Jacobs P, Bell NR, Klarenbach S. Refining the measurement of the economic burden of chronic diseases in Canada. Chronic Dis Can. 2004;25(1):13-21.
64. Schneider KM, O’Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States’ Medicare population. Health Qual Life Outcomes. 2009;7(82):82.
65. Xakellis GC. Are patients who use a generalist physician healthier than those who seek specialty care directly? Fam Med. 2005;37(10): 719-726.
66. Paez KA, Zhao L, Hwang W. Rising out-of-pocket spending for chronic conditions: a ten-year trend. Health Aff. 2009;28(1):15-25.
67. Graves N, Courtney M, Edwards H, Chang A, Parker A, Finlayson K. Cost-effectiveness of an intervention to reduce emergency readmissions to hospital among older patients. PLoS One. 2009;4(10): e7455.
68. Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff. 2001;20(6): 267-278.
69. Schoen C, Osborn R, Squires D, Doty MM, Pierson R, Applebaum S. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff. 2010;29(12):2323-2334.
70. Schoenberg NE, Kim H, Edwards W, Fleming ST. Burden of common multiple-morbidity constellations on out-of-pocket medical expenditures among older adults. Gerontologist. 2007;47(4):423-437.
71. O’Toole J, Hambly R, Cox AM, O’Shea B, Darker C. Methadonemaintained patients in primary care have higher rates of chronic disease and multimorbidity, and use health services more intensively than matched controls. Eur J Gen Pract. 2014;20(4):275-280.
72. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27(6):671-678.
73. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473.
74. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146(2):250-257.
75. Cherubini A, Signore SD, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58(9): 1791-1796.
76. Drummond MF, Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7(4):561-573.
77. O’brien B. Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of trials? Med Care. 1996;34(12 Suppl): DS99-DS108.
78. Ramsey S, Willke R, Briggs A, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value health. 2005;8(5):521-533.
79. Coventry P, Lovell K, Dickens C, et al. Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease. BMJ. 2015;350.
80. Jäger C, Freund T, Steinhäuser J, Joos S, Wensing M, Szecsenyi J. A tailored implementation intervention to implement recommendations addressing polypharmacy in multimorbid patients: study protocol of a cluster randomized controlled trial. Trials. 2013;14(1):420.
81. Bozorgmehr K, Szecsenyi J, Ose D, et al. Practice network-based care management for patients with type 2 diabetes and multiple comorbidities (GEDIMAplus): study protocol for a randomized controlled trial. Trials. 2014;15:243.
82. Hsieh HM, Gu SM, Shin SJ, Kao HY, Lin YC, Chiu HC. Costeffectiveness of a diabetes pay-for-performance program in diabetes patients with multiple chronic conditions. PLoS One. 2015;10(7): e0133163.
83. Ritzwoller DP, Glasgow RE, Sukhanova AY, et al. Economic analyses of the Be Fit Be Well program: a weight loss program for community health centers. J Gen Intern Med. 2013;28(12):1581-1588.
84. Vila A, Villegas E, Cruanyes J, et al. Cost-effectiveness of a Barcelona home care program for individuals with multimorbidity. J Am Geriatr Soc. 2015;63(5):1017-1024.
85. Drummond MF, McGuire A. Economic Evaluation in Health Care: Merging Theory with Practice. New York, NY: Oxford University Press; 2001.
86. Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value Health. 2003;6(1):9-17.
87. Katon WJ, Lin EHB, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611-2620.
88. Katon W, Russo J, Lin EH, et al. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch GenPsychiatry. 2012;69(5):506-514.
89. Schmittdiel J, Vijan S, Fireman B, Lafata JE, Oestreicher N, Selby JV. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care. 2007;45(4): 315-321.
90. Lindström J, Peltonen M, Eriksson J, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56(2):284-293.
91. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-1789.
92. DPPR Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875.
93. Tosteson A, Jönsson B, Grima D, O’Brien B, Black D, Adachi J. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteopor Int. 2001;12(10):849-857.
94. Sprangers MA, Schwartz CE. Integrating response shift into healthrelated quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507-1515.
95. McPhail S, Haines T. The response shift phenomenon in clinical trials. J Clin Res Best Pract. 2010;6(2):1-8.
96. Groot W. Adaptation and scale of reference bias in self-assessments of quality of life. J Health Econ. 2000;19(3):403-420.
97. Menzel P, Dolan P, Richardson J, Olsen JA. The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis. Soc Sci Med. 2002;55(12):2149-2158.
98. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke. 2001;32(6): 1425-1429.
99. McPhail S, Comans T, Haines T. Evidence of disagreement between patient-perceived change and conventional longitudinal evaluation of change in health-related quality of life among older adults. Clin Rehabil. 2010;24(11):1036-1044.
100. Howard GS, Dailey PR. Response-shift bias: a source of contamination of self-report measures. J Appl Psychol. 1979;64(2):144.
101. Daltroy LH, Larson MG, Eaton HM, Phillips CB, Liang MH. Discrepancies between self-reported and observed physical function in the elderly: the influence of response shift and other factors. Soc Sci Med. 1999;48(11):1549-1561.
102. McPhail S, Haines T. Response shift, recall bias and their effect on measuring change in health-related quality of life amongst older hospital patients. Health Qual Life Outcomes. 2010;8:65.
103. Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48(11):1531-1548.
104. Oort FJ. Using structural equation modeling to detect response shifts and true change. Qual Life Res. 2005;14(3):587-598.
105. Ahmed S, Mayo NE, Wood-Dauphinee S, Hanley JA, Cohen SR. The structural equation modeling technique did not show a response shift, contrary to the results of the then test and the individualized approaches. J Clin Epidemiol. 2005;58(11):1125-1133.
106. Snyder C, Aaronson N, Choucair A, et al. Implementing patientreported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305-1314.
107. Hickey A, Barker M, McGee H, O’Boyle C. Measuring health-related quality of life in older patient populations. Pharmacoeconomics. 2005;23(10):971-993.
108. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64(3):510-519.
109. McPhail S, Beller E, Haines T. Reference bias: presentation of extreme health states prior to EQ-VAS improves health-related quality of life scores. A randomised cross-over trial. Health Qual Life Outcomes. 2010;8(1):146.
110. Sneeuw KC, Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol. 2002;55(11):1130-1143.
111. McPhail S, Beller E, Haines T. Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement. Med Care. 2008;46(11):1140-1148.
112. Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care. 2005;43(5):493.
113. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622.
114. Panagioti M, Richardson G, Murray E, et al. Reducing Care Utilisation through Self-management Interventions (RECURSIVE): A Systematic Review and Meta-analysis. Southampton, UK: Queen’s Printer and Controller of HMSO; 2014.
115. Russell LB. Preventing chronic disease: an important investment, but don’t count on cost savings. Health Aff. 2009;28(1):42-45.
116. Thompson KM, Tebbens RJD. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26(6):1423-1440.
117. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J. 2001;22(11):919-925.
118. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial. BMJ. 2005;330(7493):707.
119. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354(9188):1457-1463.
120. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800-1806.
121. Fagan K, Zhao EY, Horsfall L, et al. Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change? Intern Med J. 2014;44(9):865-872.
122. Price E, Baker R, Krause J, Keen C. Organisation of services for people with cardiovascular disorders in primary care: transfer to primary care or to specialist-generalist multidisciplinary teams? BMC Fam Pract. 2014;15:158.
123. Sanmuganathan P, Ghahramani P, Jackson P, Wallis E, Ramsay L. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265-271.
124. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542): 1155-1163.
125. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317(7154):307-312.
126. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315(7122):1577-1582.
127. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-1965.
128. McPhail SM, Schippers M, Maher CA, Marshall AL. Patient preferences for receiving remote-communication support for lifestyle physical activity behaviour change: the perspective of patients with musculoskeletal disorders from three hospital services. BioMed Res Int. 2015;2015:390352.
129. Dranove D. Pricing by non-profit institutions. The case of hospital cost-shifting. J Health Econ. 1988;7(1):47-57.
130. Wu VY. Hospital cost shifting revisited: new evidence from the balanced budget act of 1997. Int J Health Care Finance Econ. 2010;10(1):61-83.
131. Fuchs VR. Cost shifting does not reduce the cost of health care. JAMA. 2009;302(9):999-1000.
132. Frakt AB. How much do hospitals cost shift? A review of the evidence. Milbank Q. 2011;89(1):90-130.
133. Murray R. Setting hospital rates to control costs and boost quality: the Maryland experience. Health Aff. 2009;28(5):1395-1405.
134. Duckett S. The Australian Health Care System. New York, NY: Oxford University Press; 2004.
135. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. Health Aff. 2011; 30(12):2437-2448.
136. Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK. Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States. BMJ. 2004;328(7440):607.
137. Chan R, Webster J. End-of-life care pathways for improving outcomes in caring for the dying. Cochrane Database Syst Rev. 2010;1:CD008006.
138. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries’ costs of care in the last year of life. Health Aff. 2001;20(4):188-195.
139. Frost DW, Cook DJ, Heyland DK, Fowler RA. Patient and healthcare professional factors influencing end-of-life decisionmaking during critical illness: a systematic review. Crit Care Med. 2011;39(5):1174-1189.
140. Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitusrelated comorbidities. J Diabetes Complicat. 2015;29(4):529-533.
141. Tonelli M, Wiebe N, Guthrie B, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859-866.
142. May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. BMC Health Serv Res. 2014;14(1):1-11.
143. Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol. 2012; 65(10):1041-1051.
144. Glasgow RE, Chambers D. Developing robust, sustainable, implementation systems using rigorous, rapid and relevant science. Clin Transl Sci. 2012;5(1):48-55.
145. Parchman M, Scoglio C, Schumm P. Understanding the implementation of evidence-based care: a structural network approach. Implement Sci. 2011;6(1):14.